Tofacitinib alone or with mesalamine for ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study tests whether taking tofacitinib alone works as well as taking tofacitinib with mesalamine for people with ulcerative colitis who are already in remission. It aims to see if one medication can be stopped without causing a flare-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of ulcerative colitis through a colonoscopy and biopsy.
- Your disease must be in remission (no symptoms) for at least 3 months while taking tofacitinib and mesalamine.
- You cannot have active disease, Crohn's disease, or other types of colitis.
- You cannot be pregnant, breastfeeding, or planning pregnancy in the next 2 years.
- You must not have a history of blood clots, heart attack within 3 months, heart failure, or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if combining two medicines, vedolizumab and tofacitinib, helps control moderate to severe ulcerative colitis. It may be an option if other treatments, like anti-TNF drugs, haven't worked well for you.
This study looks at how tofacitinib (and related medicines) may affect clotting and blood-platelet function, and whether this could relate to blood clot risk. It includes detailed blood and stool/colonoscopy-related testing in adults with ulcerative colitis and in some people without it.
This study follows people with moderately to severely active ulcerative colitis who are taking the medication tofacitinib (Xeljanz). It aims to track any safety concerns in a real-world setting, using information already collected in a European registry (UR-CARE).
This trial tests if combining two medications, infliximab and tofacitinib, works better than standard treatment for adults hospitalized with a severe flare of ulcerative colitis. If you have not been on these drugs before and meet certain health criteria, you may be able to join.
This study tests whether combining two medicines—methotrexate and tofacitinib—works better for people with a specific type of rheumatoid arthritis. It may be a good fit if you have moderate to severe arthritis, have had a joint biopsy that shows a certain cell pattern, and haven't used similar treatments before.
This trial tests if the drug tofacitinib can help people whose heart inflammation from cancer immunotherapy (called ICI-related myocarditis) does not improve with steroids. If you have this condition, this study may offer a new treatment option.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.